iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
71 hedge funds and large institutions have $907M invested in iTeos Therapeutics in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
48% more capital invested
Capital invested by funds: $614M → $907M (+$292M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more funds holding
Funds holding: 54 → 71 (+17)
5.55% more ownership
Funds ownership: 71.2% → 76.75% (+5.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$26.2M |
| 2 |
BlackRock
New York
|
+$10.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.74M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.65M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.29M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.17M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.67M |
ITOS Hedge Fund Activity: Q4 2020 in Review
71 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2020, worth a combined $907M — up 48% from $614M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ITOS positions and 5 closed out — a net gain of 17 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $26.2M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $10M sold.
- 71 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2020, up from 54 in Q3 2020.
- Funds reported $907M of iTeos Therapeutics stock for Q4 2020, up 48% quarter-over-quarter.
- 22 funds opened new iTeos Therapeutics positions in Q4 2020 and 5 closed out, a net change of +17 holders.
- The largest iTeos Therapeutics buyer in Q4 2020 was Janus Henderson Group, an estimated $26.2M added.
- The largest iTeos Therapeutics seller in Q4 2020 was PFM Health Sciences, an estimated $10M sold.
Based on aggregated 13F filings for Q4 2020.